Last ¥3,485 JPY
Change Today +40.00 / 1.16%
Volume 196.5K
4585 On Other Exchanges
Symbol
Exchange
Tokyo
As of 1:00 AM 11/21/14 All times are local (Market data is delayed by at least 15 minutes).

umn pharma inc (4585) Snapshot

Open
¥3,430
Previous Close
¥3,445
Day High
¥3,490
Day Low
¥3,380
52 Week High
12/3/13 - ¥4,330
52 Week Low
03/27/14 - ¥2,020
Market Cap
33.3B
Average Volume 10 Days
146.8K
EPS TTM
¥-491.59
Shares Outstanding
9.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UMN PHARMA INC (4585)

Related News

No related news articles were found.

umn pharma inc (4585) Related Businessweek News

No Related Businessweek News Found

umn pharma inc (4585) Details

UMN Pharma Inc. develops and manufactures biopharmaceuticals in Japan and internationally. Its products include UMN-0502, a seasonal influenza vaccine; UMN-0501 and UMN-0901, which are pandemic influenza vaccines; UMN-2003, a norovirus/rotavirus vaccine; and UMN-2002, a norovirus vaccine. The company was founded in 2004 and is headquartered in Yokohama, Japan.

91 Employees
Last Reported Date: 03/31/14
Founded in 2004

umn pharma inc (4585) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

umn pharma inc (4585) Key Developments

UMN Pharma Inc. to Report Q3, 2014 Results on Oct 31, 2014

UMN Pharma Inc. announced that they will report Q3, 2014 results on Oct 31, 2014

UMN Pharma Inc. Reports Consolidated Earnings Results for the First Half Ended June 30, 2014; Provides Earnings Forecast for the Year Ending December 31, 2014, 2015, 2016 and 2017

UMN Pharma Inc. reported consolidated earnings results for the first half ended June 30, 2014. For the quarter, the company's net sales were JPY 1,078 million compared to JPY 24 million a year ago. Operating loss was JPY 1,796 million compared to JPY 1,497 million a year ago. Ordinary loss was JPY 1,967 million compared to JPY 1,641 million a year ago. Net loss was JPY 1,677 million or JPY 198.63 per share compared to JPY 1,166 million a year ago. The company provided earnings forecast for the year ending December 31, 2014, 2015, 2016 and 2017. For the year ending December 31, 2014, the company expects net sales of JPY 2,186 million, operating loss of JPY 3,210 million, ordinary loss of JPY 3,424 million and net loss of JPY 2,436 million or JPY 289.11 per share. For the year ending December 31, 2015, the company expects net sales to be in the range of JPY 6,660 million to JPY 7,663 million, operating income to be in the range of JPY 337 million to JPY 1,438 million, ordinary income to be in the range of JPY 161 million to JPY 1,263 million and net income to be in the range of JPY 118 million to JPY 950 million. For the year ending December 31, 2016, the company expects net sales to be in the range of JPY 7,649 million to JPY 8,850 million, operating income to be in the range of JPY 358 million to JPY 1,672 million, ordinary income to be in the range of JPY 214 million to JPY 1,529 million and net income to be in the range of JPY 153 million to JPY 1,145 million. For the year ending December 31, 2017, the company expects net sales to be in the range of JPY 10,834 million to JPY 11,735 million, operating income to be in the range of JPY 1,961 million to JPY 3,499 million, ordinary income to be in the range of JPY 1,846 million to JPY 3,384 million and net income to be in the range of JPY 1,461 million to JPY 2,611 million.

UMN Pharma Inc., Q2 2014 Earnings Call, Jul 31, 2014

UMN Pharma Inc., Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4585:JP ¥3,485.00 JPY +40.00

4585 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4585.
View Industry Companies
 

Industry Analysis

4585

Industry Average

Valuation 4585 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 24.0x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 19.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UMN PHARMA INC, please visit www.umnpharma.com/en. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.